TP53 and cancer: Our discovery that CHD1/IL7R inhibition enhances platinum sensitivity in p53R175G cells identifies novel therapeutic targets; future in vivo and clinical validation will strengthen translational potential and enable personalized strategies for p53-mutant cancers.